Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1996 Feb;64(2):548–556. doi: 10.1128/iai.64.2.548-556.1996

Variation of Brucella abortus 2308 infection in BALB/c mice induced by prior vaccination with salt-extractable periplasmic proteins from Brucella abortus 19.

G W Pugh Jr 1, L B Tabatabai 1
PMCID: PMC173800  PMID: 8550206

Abstract

The study compared the immune and protective responses induced in BALB/c mice vaccinated with six salt-extractable periplasmic protein fractions (Brucella cell surface proteins [BCSP]) of Brucella abortus 19 and later challenge exposed with B. abortus 2308. BCSP70 was precipitated with ammonium sulfate at 70% saturation, and BCSP100 was precipitated with ammonium sulfate at 100% saturation by use of supernatant fluid of BCSP70 that had been precipitated with 70% ammonium sulfate. Four subfractions were separated from BCSP100 by anion-exchange high-performance liquid chromatography (HPLC). Monophosphoryl lipid A (MPL) from Salmonella typhimurium Re mutant strain was used as a potential immune response modifier in some vaccines. Reduced or increased numbers of CFU and increased spleen size in the principal groups of mice relative to that of the nonvaccinated control group were considered protectiveness or virulence (survival) criteria. Results indicated that vaccines prepared from BCSP70 and BCSP100 were moderately protective and immunogenic. The subfractions designated BCSP100-A through BCSP100-D purified by anion-exchange HPLC were not protective when MPL was not used as an immune response modifier. However, two subfractions were associated with significant (P < 0.05) increases in CFU per spleen and splenomegaly in vaccinated mice compared with those in nonvaccinated challenge-exposed mice. MPL enhanced protection or was neutral when used with BCSP70, BCSP100, BCSP100-C, and BCSP100-D. Serologic results of an enzyme-linked immunosorbent assay indicated that MPL modulated the immunoglobulin G responses induced by BCSP70, BCSP100, and subfraction BCSP100-B vaccines only. The overall results suggest that certain proteinaceous periplasmic fractions might serve as virulence or survival factors in B. abortus infections.

Full Text

The Full Text of this article is available as a PDF (307.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Araya L. N., Elzer P. H., Rowe G. E., Enright F. M., Winter A. J. Temporal development of protective cell-mediated and humoral immunity in BALB/c mice infected with Brucella abortus. J Immunol. 1989 Nov 15;143(10):3330–3337. [PubMed] [Google Scholar]
  2. Bascoul S., Cannat A., Huguet M. F., Serre A. Studies on the immune protection to murine experimental brucellosis conferred by Brucella fractions. I. Positive role of immune serum. Immunology. 1978 Aug;35(2):213–221. [PMC free article] [PubMed] [Google Scholar]
  3. Beauclair K. D., Khansari D. N. Protection of mice against Brucella abortus by immunization with polyclonal anti-idiotype antibodies. Immunobiology. 1990 Feb;180(2-3):208–220. doi: 10.1016/s0171-2985(11)80329-3. [DOI] [PubMed] [Google Scholar]
  4. Beck B. L., Tabatabai L. B., Mayfield J. E. A protein isolated from Brucella abortus is a Cu-Zn superoxide dismutase. Biochemistry. 1990 Jan 16;29(2):372–376. doi: 10.1021/bi00454a010. [DOI] [PubMed] [Google Scholar]
  5. Belzer C. A., Tabatabai L. B., Deyoe B. L. Differentiation by western blotting of immune responses of cattle vaccinated with Brucella abortus strain 19 or infected experimentally or naturally with virulent Brucella abortus. Vet Microbiol. 1991 Mar;27(1):79–90. doi: 10.1016/0378-1135(91)90064-m. [DOI] [PubMed] [Google Scholar]
  6. Bosseray N. Immunity to Brucella in mice vaccinated with a fraction (F8) or a killed vaccine (H38) with or without adjuvant. Level and duration of immunity in relation to dose of vaccine, recall injection and age of mice. Br J Exp Pathol. 1978 Aug;59(4):354–365. [PMC free article] [PubMed] [Google Scholar]
  7. Bricker B. J., Tabatabai L. B., Deyoe B. L., Mayfield J. E. Conservation of antigenicity in a 31-kDa Brucella protein. Vet Microbiol. 1988 Dec;18(3-4):313–325. doi: 10.1016/0378-1135(88)90096-x. [DOI] [PubMed] [Google Scholar]
  8. Cheers C. Pathogenesis and cellular immunity in experimental murine brucellosis. Dev Biol Stand. 1984;56:237–246. [PubMed] [Google Scholar]
  9. Cheers C., Young A. M. Serum colony stimulating activity and colony forming cells in murine brucellosis: relationship to immunopathology. Microb Pathog. 1987 Sep;3(3):185–194. doi: 10.1016/0882-4010(87)90095-7. [DOI] [PubMed] [Google Scholar]
  10. Corbeil L. B., Schurig G. G., Bier P. J., Winter A. J. Bovine veneral vibriosis: antigenic variation of the bacterium during infection. Infect Immun. 1975 Feb;11(2):240–244. doi: 10.1128/iai.11.2.240-244.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dubray G. Protective antigens in brucellosis. Ann Inst Pasteur Microbiol. 1987 Jan-Feb;138(1):84–87. doi: 10.1016/0769-2609(87)90080-9. [DOI] [PubMed] [Google Scholar]
  12. Ellwood D. C., Keppie J., Smith H. The chemical basis of the virulence of Brucella abortus. 8. The identity of purified immunogenic material from culture filtrate and from the cell-wall of Brucella abortus grown in vitro. Br J Exp Pathol. 1967 Feb;48(1):28–39. [PMC free article] [PubMed] [Google Scholar]
  13. Elzer P. H., Jacobson R. H., Jones S. M., Nielsen K. H., Douglas J. T., Winter A. J. Antibody-mediated protection against Brucella abortus in BALB/c mice at successive periods after infection: variation between virulent strain 2308 and attenuated vaccine strain 19. Immunology. 1994 Aug;82(4):651–658. [PMC free article] [PubMed] [Google Scholar]
  14. Frenchick P. J., Markham R. J., Cochrane A. H. Inhibition of phagosome-lysosome fusion in macrophages by soluble extracts of virulent Brucella abortus. Am J Vet Res. 1985 Feb;46(2):332–335. [PubMed] [Google Scholar]
  15. Griffiths E. Environmental regulation of bacterial virulence--implications for vaccine design and production. Trends Biotechnol. 1991 Sep;9(9):309–315. doi: 10.1016/0167-7799(91)90101-m. [DOI] [PubMed] [Google Scholar]
  16. Halling S. M., Detilleux P. G., Tatum F. M., Judge B. A., Mayfield J. E. Deletion of the BCSP31 gene of Brucella abortus by replacement. Infect Immun. 1991 Nov;59(11):3863–3868. doi: 10.1128/iai.59.11.3863-3868.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Henricson B. E., Benjamin W. R., Vogel S. N. Differential cytokine induction by doses of lipopolysaccharide and monophosphoryl lipid A that result in equivalent early endotoxin tolerance. Infect Immun. 1990 Aug;58(8):2429–2437. doi: 10.1128/iai.58.8.2429-2437.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Hoffman M. "Superantigens" may shed light on immune puzzle. Science. 1990 May 11;248(4956):685–686. doi: 10.1126/science.2333520. [DOI] [PubMed] [Google Scholar]
  19. Jacques I., Olivier-Bernardin V., Dubray G. Induction of antibody and protective responses in mice by Brucella O-polysaccharide-BSA conjugate. Vaccine. 1991 Dec;9(12):896–900. doi: 10.1016/0264-410x(91)90010-4. [DOI] [PubMed] [Google Scholar]
  20. Kurtz R. S., Berman D. T. Influence of endotoxin-protein in immunoglobulin G isotype responses of mice to Brucella abortus lipopolysaccharide. Infect Immun. 1986 Dec;54(3):728–734. doi: 10.1128/iai.54.3.728-734.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  22. Latimer E., Simmers J., Sriranganathan N., Roop R. M., 2nd, Schurig G. G., Boyle S. M. Brucella abortus deficient in copper/zinc superoxide dismutase is virulent in BALB/c mice. Microb Pathog. 1992 Feb;12(2):105–113. doi: 10.1016/0882-4010(92)90113-3. [DOI] [PubMed] [Google Scholar]
  23. Loeb M. R., Smith D. H. Outer membrane protein composition in disease isolates of Haemophilus influenzae: pathogenic and epidemiological implications. Infect Immun. 1980 Dec;30(3):709–717. doi: 10.1128/iai.30.3.709-717.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Misfeldt M. L. Microbial "superantigens". Infect Immun. 1990 Aug;58(8):2409–2413. doi: 10.1128/iai.58.8.2409-2413.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Moreno E., Kurtz R. S., Berman D. T. Induction of immune and adjuvant immunoglobulin G responses in mice by Brucella lipopolysaccharide. Infect Immun. 1984 Oct;46(1):74–80. doi: 10.1128/iai.46.1.74-80.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Pardon P. Resistance against a subcutaneous Brucella challenge of mice immunized with living or dead Brucella or by transfer of immune serum. Ann Immunol (Paris) 1977 Nov-Dec;128(6):1025–1037. [PubMed] [Google Scholar]
  27. Phillips M., Deyoe B. L., Canning P. C. Protection of mice against Brucella abortus infection by inoculation with monoclonal antibodies recognizing Brucella O-antigen. Am J Vet Res. 1989 Dec;50(12):2158–2161. [PubMed] [Google Scholar]
  28. Phillips M., Pugh G. W., Jr, Deyoe B. L. Chemical and protective properties of Brucella lipopolysaccharide obtained by butanol extraction. Am J Vet Res. 1989 Mar;50(3):311–317. [PubMed] [Google Scholar]
  29. Phillips M., Pugh G. W., Jr, Deyoe B. L. Duration of strain 2308 infection and immunogenicity of Brucella abortus lipopolysaccharide in five strains of mice. Am J Vet Res. 1989 Mar;50(3):318–322. [PubMed] [Google Scholar]
  30. Plommet M., Plommet A. M. Anti-Brucella cell-mediated immunity in mice vaccinated with a cell-wall fraction. Ann Rech Vet. 1987;18(4):429–437. [PubMed] [Google Scholar]
  31. Pugh G. W., Jr, Phillips M., Tabatabai L. B., McDonald T. J. Unresponsiveness of vaccinated BALB/c mice to a second inoculation of lipopolysaccharide from Brucella abortus strain 2308. Vet Microbiol. 1991 Jan;26(1-2):167–177. doi: 10.1016/0378-1135(91)90053-i. [DOI] [PubMed] [Google Scholar]
  32. Pugh G. W., Jr, Tabatabai L. B. Alteration of protective and serologic responses in BALB/c mice vaccinated with chemically modified versus nonmodified proteins of Brucella abortus 19. Infect Immun. 1994 Dec;62(12):5327–5334. doi: 10.1128/iai.62.12.5327-5334.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Pugh G. W., Jr, Tabatabai L. B., Bricker B. J., Mayfield J. E., Phillips M., McDonald T. J., Zehr E. S. Identification of a virulence factor for Brucella abortus infection in BALB/c mice. Am J Vet Res. 1989 Jun;50(6):887–892. [PubMed] [Google Scholar]
  34. Pugh G. W., Jr, Tabatabai L. B., Bricker B. J., Mayfield J. E., Phillips M., Zehr E. S., Belzer C. A. Immunogenicity of Brucella-extracted and recombinant protein vaccines in CD-1 and BALB/c mice. Am J Vet Res. 1990 Sep;51(9):1413–1420. [PubMed] [Google Scholar]
  35. Pugh G. W., Jr, Tabatabai L. B., Phillips M., McDonald T. J. Establishment of dose-response relationships in BALB/c mice, using Brucella cell surface protein and lipopolysaccharide. Am J Vet Res. 1991 Feb;52(2):261–268. [PubMed] [Google Scholar]
  36. Pugh G. W., Jr, Zehr E. S., Meador V. P., Phillips M., McDonald T. J., Deyoe B. L. Immunologic, histopathologic, and bacteriologic responses of five strains of mice to Brucella abortus strain 2308. Am J Vet Res. 1989 Mar;50(3):323–328. [PubMed] [Google Scholar]
  37. Schwab J. H. Suppression of the immune response by microorganisms. Bacteriol Rev. 1975 Jun;39(2):121–143. doi: 10.1128/br.39.2.121-143.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Smith R., 3rd, Adams L. G., Sowa B. A., Ficht T. A. Induction of lymphocyte responsiveness by the outer membrane-peptidoglycan complex of rough strains of Brucella abortus. Vet Immunol Immunopathol. 1990 Sep;26(1):31–48. doi: 10.1016/0165-2427(90)90130-k. [DOI] [PubMed] [Google Scholar]
  39. Sriranganathan N., Boyle S. M., Schurig G., Misra H. Superoxide dismutases of virulent and avirulent strains of Brucella abortus. Vet Microbiol. 1991 Feb 15;26(4):359–366. doi: 10.1016/0378-1135(91)90029-f. [DOI] [PubMed] [Google Scholar]
  40. Stabel T. J., Mayfield J. E., Tabatabai L. B., Wannemuehler M. J. Oral immunization of mice with attenuated Salmonella typhimurium containing a recombinant plasmid which codes for production of a 31-kilodalton protein of Brucella abortus. Infect Immun. 1990 Jul;58(7):2048–2055. doi: 10.1128/iai.58.7.2048-2055.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Stabel T. J., Sha Z., Mayfield J. E. Periplasmic location of Brucella abortus Cu/Zn superoxide dismutase. Vet Microbiol. 1994 Feb;38(4):307–314. doi: 10.1016/0378-1135(94)90149-x. [DOI] [PubMed] [Google Scholar]
  42. Stevens M. G., Olsen S. C., Pugh G. W., Jr, Brees D. Comparison of immune responses and resistance to brucellosis in mice vaccinated with Brucella abortus 19 or RB51. Infect Immun. 1995 Jan;63(1):264–270. doi: 10.1128/iai.63.1.264-270.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Stevens M. G., Olsen S. C., Pugh G. W., Jr, Palmer M. V. Immune and pathologic responses in mice infected with Brucella abortus 19, RB51, or 2308. Infect Immun. 1994 Aug;62(8):3206–3212. doi: 10.1128/iai.62.8.3206-3212.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Stevens M. G., Tabatabai L. B., Olsen S. C., Cheville N. F. Immune responses to superoxide dismutase and synthetic peptides of superoxide dismutase in cattle vaccinated with Brucella abortus strain 19 or RB51. Vet Microbiol. 1994 Aug 15;41(4):383–389. doi: 10.1016/0378-1135(94)90034-5. [DOI] [PubMed] [Google Scholar]
  45. Tabatabai L. B., Deyoe B. L., Patterson J. M. Immunogenicity of Brucella abortus salt-extractable proteins. Vet Microbiol. 1989 May;20(1):49–58. doi: 10.1016/0378-1135(89)90006-0. [DOI] [PubMed] [Google Scholar]
  46. Tabatabai L. B., Deyoe B. L., Ritchie A. E. Isolation and characterization of toxic fractions from Brucella abortus. Infect Immun. 1979 Nov;26(2):668–679. doi: 10.1128/iai.26.2.668-679.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Tabatabai L. B., Deyoe B. L. Specific enzyme-linked immunosorbent assay for detection of bovine antibody to Brucella abortus. J Clin Microbiol. 1984 Aug;20(2):209–213. doi: 10.1128/jcm.20.2.209-213.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Tabatabai L. B., Pugh G. W., Jr Modulation of immune responses in Balb/c mice vaccinated with Brucella abortus Cu-Zn superoxide dismutase synthetic peptide vaccine. Vaccine. 1994 Aug;12(10):919–924. doi: 10.1016/0264-410x(94)90035-3. [DOI] [PubMed] [Google Scholar]
  49. Tabatabai L. B., Pugh G. W., Jr, Stevens M. G., Phillips M., McDonald T. J. Monophosphoryl lipid A-induced immune enhancement of Brucella abortus salt-extractable protein and lipopolysaccharide vaccines in BALB/c mice. Am J Vet Res. 1992 Oct;53(10):1900–1907. [PubMed] [Google Scholar]
  50. Tam J. P., Clavijo P., Lu Y. A., Nussenzweig V., Nussenzweig R., Zavala F. Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J Exp Med. 1990 Jan 1;171(1):299–306. doi: 10.1084/jem.171.1.299. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Tam J. P. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci U S A. 1988 Aug;85(15):5409–5413. doi: 10.1073/pnas.85.15.5409. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Tatum F. M., Detilleux P. G., Sacks J. M., Halling S. M. Construction of Cu-Zn superoxide dismutase deletion mutants of Brucella abortus: analysis of survival in vitro in epithelial and phagocytic cells and in vivo in mice. Infect Immun. 1992 Jul;60(7):2863–2869. doi: 10.1128/iai.60.7.2863-2869.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Voller A., Bidwell D. E. A simple method for detecting antibodies to rubella. Br J Exp Pathol. 1975 Aug;56(4):338–339. [PMC free article] [PubMed] [Google Scholar]
  54. Winter A. J. Outer membrane proteins of Brucella. Ann Inst Pasteur Microbiol. 1987 Jan-Feb;138(1):87–89. doi: 10.1016/0769-2609(87)90081-0. [DOI] [PubMed] [Google Scholar]
  55. Winter A. J., Rowe G. E. Comparative immune responses to native cell envelope antigens and the hot sodium dodecyl sulfate insoluble fraction (PG) of Brucella abortus in cattle and mice. Vet Immunol Immunopathol. 1988 Mar;18(2):149–163. doi: 10.1016/0165-2427(88)90057-8. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES